Dataset Information


Diabetes induced microbiome dysbiosis is associated with therapy resistance in Pancreatic Ductal Adenocarcinoma (PDAC)

ABSTRACT: Pancreatic cancer is the 3rd most prevalent cause of cancer related deaths in United states alone, with over 55000 patients being diagnosed in 2019 alone and nearly as many succumbing to it. Late detection, lack of effective therapy and poor understanding of pancreatic cancer systemically contributes to its poor survival statistics. Obesity and high caloric intake linked co-morbidities like type 2 diabetes (T2D) have been attributed as being risk factors for a number of cancers including pancreatic cancer. Studies on gut microbiome has shown that lifestyle factors as well as diet has a huge effect on the microbial flora of the gut. Further, modulation of gut microbiome has been seen to contribute to effects of intensive insulin therapy in mice on high fat diet. In another study, abnormal gut microbiota was reported to contribute to development of diabetes in Db/Db mice. Recent studies indicate that microbiome and microbial dysbiosis plays a role in not only the onset of disease but also in its outcome. In colorectal cancer, Fusobacterium has been reported to promote therapy resistance. Certain intra-tumoral bacteria have also been shown to elicit chemo-resistance by metabolizing anti-cancerous agents. In pancreatic cancer, studies on altered gut microbiome have been relatively recent. Microbial dysbiosis has been observed to be associated with pancreatic tumor progression. Modulation of microbiome has been shown to affect response to anti-PD1 therapy in this disease as well. However, most of the studies in pancreatic cancer and microbiome have remained focused om immune modulation. In the current study, we observed that in a T2D mouse model, the microbiome changed significantly as the hyperglycemia developed in these animals. Our results further showed that, tumors implanted in the T2D mice responded poorly to Gemcitabine/Paclitaxel (Gem/Pac) standard of care compared to those in the control group. A metabolomic reconstruction of the WGS of the gut microbiota further revealed that an enrichment of bacterial population involved in drug metabolism in the T2D group.

INSTRUMENT(S): Illumina HiSeq 2500

ORGANISM(S): mouse gut metagenome

SUBMITTER: Sulagna Banerjee 

PROVIDER: E-MTAB-8739 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image


Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma.

Kesh Kousik K   Mendez Roberto R   Abdelrahman Leila L   Banerjee Santanu S   Banerjee Sulagna S  

Microbial cell factories 20200324 1

Resistance to therapy is one of the major factors that contribute to dismal survival statistics in pancreatic cancer. While there are many tumor intrinsic and tumor microenvironment driven factors that contribute to therapy resistance, whether pre-existing metabolic diseases like type 2 diabetes (T2D) contribute to this has remained understudied. It is well accepted that hyperglycemia associated with type 2 diabetes changes the gut microbiome. Further, hyperglycemia also enriches for a "stem-lik  ...[more]

Similar Datasets

2019-09-11 | PXD013452 | Pride
2022-04-04 | PXD018885 | Pride
2022-07-26 | E-MTAB-11636 | biostudies-arrayexpress
2014-02-04 | E-GEOD-54290 | biostudies-arrayexpress
2013-01-02 | E-GEOD-43238 | biostudies-arrayexpress
2015-08-03 | E-GEOD-40670 | biostudies-arrayexpress
2014-06-15 | E-GEOD-54224 | biostudies-arrayexpress
2023-07-02 | E-MTAB-11277 | biostudies-arrayexpress
2022-02-01 | E-MTAB-10160 | biostudies-arrayexpress
2015-05-22 | E-MTAB-3590 | biostudies-arrayexpress